echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > More than 200 jobs have been cut in France and 149 in Amgen!

    More than 200 jobs have been cut in France and 149 in Amgen!

    • Last Update: 2019-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to La Montagne, French media, on November 12, MSD chibret Mirabel, the production and research base in Riom, France, will cut more than one third of its staff and face the possibility of overall sale At the end of October, MSD has issued a wave of layoffs notice, and will lay off nearly 500 sales and headquarters business teams in the United States early next year It is reported that Liyong's base in France is specialized in the manufacture and packaging of sterile drugs, including ophthalmic drugs and antibiotics It has been established for 41 years and is one of the main factories of Merck in France and even in Europe At present, there are 584 employees here, and the layoff will involve about 200 jobs A spokesman for MSD chibret said that the project to restructure and rebuild the Ryong plant was aimed at dealing with the structural change of MSD chibret "The global economic situation has changed, and the multinational company is no longer interested in investing in France Now they are more interested in China, Ireland or India," said Claude dagos of the French workers' Union The reorganization of Liyong base will be carried out in two stages First, the laboratory of the research center was closed At present, the center has 106 employees, and has become the target of the proposed divestment in 2015, which has not been implemented due to strikes and other reasons "In recent years, the number of toxicology studies commissioned to research centres has decreased significantly." Relevant person in charge said Second, reorganize the production part "In the face of the continuous decline in production in recent years, the production center is under utilized its production line, so the company plans to restructure its production activities." In the end, he said, 101 jobs could be eliminated More measures have been considered in the restructuring plan In addition to the possible 207 layoffs, the company also announced plans to find new buyers for the Ryong production and research base, which it believes "is a sustainable way to bring more production, maintain the vitality and employment of the base." Neuroscience research and development is not easy to do: Recently, Amgen officially laid off 149 people Recently, Amgen submitted the workers' adjustment and retraining notice act in Massachusetts, which means that its plan to lay off 149 people by the end of the year officially began to be implemented, but Amgen will retain its operation and development business in the Cambridge base of the state A few weeks ago, Amgen revealed it was cutting its neuroscience business off the east coast of the United States, a move that could threaten about 180 jobs Amgen's business in Cambridge research base mainly focuses on neuroscience and employs R & D personnel who are proficient in pharmaceutical chemistry, pharmacokinetics and drug metabolism, genetics, cell biology and toxicology However, with the gradual withdrawal of Amgen's R & D strategy from the field of neuroscience, the current staffing basically exceeds the requirements In July this year, Amgen, Novartis and banner Alzheimer's Institute jointly announced the termination of two key phase II / III studies of BACE1 inhibitor cnp520 (umibecestat) for the prevention of Alzheimer's disease The results showed that the cognitive function of patients receiving drug prevention deteriorated After that, Amgen decided to withdraw from the R & D program and neuroscience R & D Although Amgen itself withdrew from neuroscience research, it continued to participate in the field in other ways In 2012, Amgen purchased human genetics research and analysis company decode for $415 million, which helped Amgen enter the genetics of nervous system diseases In mid October, Lilly announced that it would close its ERL wood Neuroscience Center in Surrey by the end of 2020, leading to about 80 layoffs in the neuroscience department and two-thirds of its staff to be transferred to the United States In July 2018, Pfizer also announced to give up research and development of new neuroscience projects, including research projects for Alzheimer's disease and Parkinson's disease; in October, Pfizer invested in the launch of a new company, cerevel therapeutics, to continue to participate in the development of therapies for central nervous system diseases in the form of investment Reference source: [1] Amgen to cut 149 staff in return from neuroscience R & D [2] Merck shutters French research site in a reorganization aim at eliminating more than 200 jobs
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.